Sunday 15 October 2017 | |
| 7.30 -08.30 AM | Registration |
| 8.30 AM | Workshop opening |
| Session 1: Pharmacokinetics & Pharmacodynamics of New & Repurposed TB Drugs Chairs: Rob Aarnoutse & Rovina Ruslami | |
| 8.45 AM | Searching for a Universal Regimen for Tuberculosis Treatment with a Shorter Duration of Therapy |
| Abstract presentations | |
| 9.15 AM | Exposure-Response Analysis of Lee 1810, a Lead Spectinamide Antibiotic in Mycobacterium tuberculosis Infected Mice |
| 9.30 AM | Improved efficacy of a cofactor-independent InhA inhibitor revealed by the C3HeB/ FeJ mouse model Gregory Robertson - Colorado State University, USA |
| 9.45 AM | Pharmacokinetic modeling and simulation of pretomanid in pulmonary tuberculosis patients Michael Lyons - Colorado State University, USA |
| 10.00 AM | High dose rifampicin for the treatment of TB meningitis: a dose finding study Rob Aarnoutse - Radboud University Medical Center, Netherlands |
| 10.15 AM | Discussion |
| 10.30 AM | Coffee Break |
| Session 2: Pharmacokinetics & pharmacodynamics of approved TB drugs Chairs: Gerry Davies & Paolo Denti | |
| 11.00 AM | A Cardiac Risk Algorithm to Predict the Probability of Drug-Induced Torsades de Pointes with Novel Anti-TB Agents |
| Abstract presentations | |
| 11.30 AM | Optimizing the Dose of Levofloxacin: Pharmacokinetic Results from the Opti-Q Study Charles Peloquin - University of Florida, USA |
| 11.45 AM | Ototoxicity is associated with exposure to kanamycin and capreomycin in the treatment of multidrug-resistant tuberculosis Mohammed Aslshaer - University of Florida, USA |
| 12.00 PM | Pyrazinamide sterilizes necrotic lesions in tuberculosis infected lungs Veronique Dartois - Rutgers University, USA |
| 12.15 PM | Moxifloxacin as the fluoroquinolone of choice to treat TB? Jansy Sarathy - Rutgers University, USA |
| 12.30 PM | Discussion |
| 12.45 PM | Lunch |
| 13.30 PM Guided Poster Session | |
| Session 3: Population Pharmacokinetics and Pharmacokinetic-Pharmacodynamic Modelling Chairs: Khisi Mdluli & Dakshina Chilukuri | |
| 2.00 PM | Benefits of data collaboration – personalized tailoring regimens |
| Abstract presentations | |
| 2.30 PM | Pharmacokinetics of rifampicin in African children - Evaluation of the new WHO dosing guidelines Paolo Denti - University of Cape Town, South Africa |
| 2.45 PM | Prediction of increase in time-to-positivity after higher doses of rifampicin based on pharmacokinetic-pharmacodynamic modelling Robin Svensson- Uppsala University, Sweden |
| 3.00 PM | Relating rifampicin exposure to treatment response in patients with pulmonary tuberculosis – potential for treatment shortening with higher doses Elin Svensson- Radboud University Medical Center, Netherlands |
| 3.15 PM | Population Pharmacokinetic Modeling of Clofazimine in Adult Tuberculosis Patients: Implications for Dosing Stella Belonwu - University of California, USA |
| 3.30 PM | Discussion |
| 3.45 PM | Coffee Break |
| Session 4: Drug development and optimization: approaches and tools Chairs: Eric Nuermberger & Charles Peloquin | |
| 4.15 PM | Translation of pre-clinical models to clinical outcomes |
| Abstract presentations | |
| 4.45 PM | Quantitative Analysis of MGIT Time to Positivity Using a Two-Part Longitudinal Model in Patients with Pulmonary Tuberculosis: A Meta-Analysis of 11 Clinical Studies Including 30 Unique Regimens JF Marier - Certara, Canada |
| 5.00 PM | Influence of Bacterial Growth Rate on Dose Optimization of Linezolid for Treatment of Tuberculosis Kristina Bigelow - Johns Hopkins University, USA |
| 5.15 PM | A pharmacokinetic/pharmacodynamic drug-drug interaction study of rifampicin and metformin in type II diabetic tuberculosis patients Lindsey te Brake - Radboud University Medical Center, Netherlands |
| 5.30 PM | Personalized tuberculosis treatment through Bayesian dosing of rifampicin Stijn van Beek - Radboud University Medical Center, Netherlands |
| 5.45 PM | Discussion |
| 6.00 PM | Reception |
| 7.00 PM | Dinner |